Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 46,429 shares of the biopharmace

Bamco Inc. NY reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 40.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,000 shares of the biopharmaceutical company

Empowered Funds LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 225,845 shares of the biopharmaceutical company

Dearborn Partners LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 69,875 shares of the biopharmaceutical company

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) Director Anthony Welters sold 18,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares of the company